Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HAJIR DADGOSTAR

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1144427568
CMS profile
323962
Location
ENCINO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,197.16

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,998.71 57
Travel and Lodging $1,198.45 3

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HAJIR DADGOSTAR

NPI 1144427568 · CMS profile ID 323962

Allopathic & Osteopathic Physicians / Ophthalmology

ENCINO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144427568?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HAJIR DADGOSTAR, NPI 1144427568, CMS profile ID 323962. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144427568?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HAJIR DADGOSTAR, NPI 1144427568, CMS profile ID 323962. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144427568?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HAJIR DADGOSTAR, NPI 1144427568, CMS profile ID 323962, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144427568?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $4,197.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–60 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $8.4803/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103527601 CMS
Regeneron Healthcare Solutions, Inc. $34.2703/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114032255 CMS
ABBVIE INC. $5.3803/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103527599 CMS
Coherus Biosciences Inc. $22.9402/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147277936 CMS
ABBVIE INC. $31.4002/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103527597 CMS
Biogen, Inc. $21.6402/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104817015 CMS
Genentech USA, Inc. $32.1702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133017596 CMS
Apellis Pharmaceuticals, Inc. $30.9602/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154021519 CMS
Regeneron Healthcare Solutions, Inc. $27.8801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114032253 CMS
Regeneron Healthcare Solutions, Inc. $30.5501/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114032251 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,501.16 29
PY2020 $372.81 7
PY2021 $511.00 15
PY2022 $2,729.31 29
PY2023 $2,862.42 52
PY2024 $4,197.16 60
PY2025 $2,824.39 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $13,054.06 11
PY2025 Principal investigator $493,287.53 540
PY2024 Recipient $4,644.69 1
PY2024 Principal investigator $121,621.53 18
PY2023 Principal investigator $389,517.12 33
PY2022 Principal investigator $320,634.16 15
PY2021 Principal investigator $164,355.50 7
PY2019 Principal investigator $22,576.50 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

551 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $3,677.40 12/24/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631459
Principal investigator 1 Ocular Therapeutix, Inc. $7,839.00 12/24/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240315
Principal investigator 1 Ocular Therapeutix, Inc. $1,585.80 12/24/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240317
Principal investigator 1 KYOWA KIRIN, INC. $2,351.66 12/18/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814495
Principal investigator 1 KYOWA KIRIN, INC. $5,258.48 12/18/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814503
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 12/17/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631463
Principal investigator 1 Boehringer Ingelheim International GmbH $2.44 12/17/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631465
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
The Retina Partners - Encino
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240321
Principal investigator 1 Boehringer Ingelheim International GmbH $85.67 12/10/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631457
Principal investigator 1 KYOWA KIRIN, INC. $2,092.46 12/10/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $121.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $121.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $121.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $121.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 12/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268851
Principal investigator 1 Boehringer Ingelheim International GmbH $1,684.80 11/27/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631451
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 11/26/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240309
Principal investigator 1 Ocular Therapeutix, Inc. $6,231.60 11/26/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240311
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 11/26/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240313
Principal investigator 1 Boehringer Ingelheim International GmbH $9,500.00 11/24/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631447
Principal investigator 1 Boehringer Ingelheim International GmbH $168.91 11/20/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631453
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631461
Principal investigator 1 Ocular Therapeutix, Inc. $4,156.00 11/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240307
Principal investigator 1 Boehringer Ingelheim International GmbH $4,660.20 11/12/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631449
Principal investigator 1 Boehringer Ingelheim International GmbH $4,854.60 11/12/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631455
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 11/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240305
Principal investigator 1 Ocular Therapeutix, Inc. $5,799.60 10/29/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240301
Principal investigator 1 Ocular Therapeutix, Inc. $12,322.80 10/29/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240303
Principal investigator 1 KYOWA KIRIN, INC. $2,127.38 10/27/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221812301
Principal investigator 1 KYOWA KIRIN, INC. $1,890.50 10/27/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221812311
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 10/17/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240299
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/17/2025 Non-covered Recipient Entity
The Retina Partners - Encino
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240323
Principal investigator 1 Ocular Therapeutix, Inc. $1,262.90 10/15/2025 Non-covered Recipient Entity
The Retina Partners - Encino
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240319
Principal investigator 1 Ocular Therapeutix, Inc. $2,125.80 10/01/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240297
Principal investigator 1 KYOWA KIRIN, INC. $724.34 09/25/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810776
Principal investigator 1 KYOWA KIRIN, INC. $2,092.46 09/25/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810782
Principal investigator 1 Ocular Therapeutix, Inc. $200.23 09/24/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240293
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 09/24/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240295
Principal investigator 1 KYOWA KIRIN, INC. $2,105.22 09/17/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810688
Principal investigator 1 KYOWA KIRIN, INC. $201.65 09/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810581
Principal investigator 1 KYOWA KIRIN, INC. $137.52 09/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810586
Principal investigator 1 Ocular Therapeutix, Inc. $10,064.70 09/03/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240289
Principal investigator 1 Ocular Therapeutix, Inc. $726.00 09/03/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240291
Principal investigator 1 Ocular Therapeutix, Inc. $1,585.80 08/29/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240287
Principal investigator 1 Boehringer Ingelheim International GmbH $408.24 08/28/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631467
Principal investigator 1 KYOWA KIRIN, INC. $2,105.22 08/22/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221809719
Principal investigator 1 Ocular Therapeutix, Inc. $2,996.00 08/13/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240285
Principal investigator 1 KYOWA KIRIN, INC. $6,289.16 08/08/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809467
Principal investigator 1 KYOWA KIRIN, INC. $6,289.16 08/08/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809475
Principal investigator 1 KYOWA KIRIN, INC. $5,502.92 08/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808344
Principal investigator 1 KYOWA KIRIN, INC. $2,973.47 08/04/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808351
Principal investigator 1 KYOWA KIRIN, INC. $5,082.08 07/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807606
Principal investigator 1 KYOWA KIRIN, INC. $1,212.62 07/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807614
Principal investigator 1 KYOWA KIRIN, INC. $2,680.52 07/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807621
Principal investigator 1 KYOWA KIRIN, INC. $2,107.22 07/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807629
Principal investigator 1 KYOWA KIRIN, INC. $3,393.68 07/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807638
Principal investigator 1 KYOWA KIRIN, INC. $2,680.52 07/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807647
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 07/28/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631433
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 07/28/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631435
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 07/28/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631437
Principal investigator 1 Boehringer Ingelheim International GmbH $146.16 07/28/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631439
Principal investigator 1 Boehringer Ingelheim International GmbH $3.66 07/28/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631441
Principal investigator 1 KYOWA KIRIN, INC. $2,105.22 07/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807197
Principal investigator 1 Ocular Therapeutix, Inc. $8,990.10 07/25/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240279
Principal investigator 1 Ocular Therapeutix, Inc. $12,442.50 07/25/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240281
Principal investigator 1 Ocular Therapeutix, Inc. $1,585.80 07/25/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240283
Principal investigator 1 Boehringer Ingelheim International GmbH $156.33 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631395
Principal investigator 1 Boehringer Ingelheim International GmbH $40.13 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631397
Principal investigator 1 Boehringer Ingelheim International GmbH $15.69 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631399
Principal investigator 1 Boehringer Ingelheim International GmbH $15.40 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631401
Principal investigator 1 Boehringer Ingelheim International GmbH $16.77 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631403
Principal investigator 1 Boehringer Ingelheim International GmbH $20.51 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631405
Principal investigator 1 Boehringer Ingelheim International GmbH $285.27 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631407
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631409
Principal investigator 1 Boehringer Ingelheim International GmbH $8.33 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631411
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631413
Principal investigator 1 Boehringer Ingelheim International GmbH $4.33 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631415
Principal investigator 1 Boehringer Ingelheim International GmbH $4.33 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631417
Principal investigator 1 Boehringer Ingelheim International GmbH $31.50 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631419
Principal investigator 1 Boehringer Ingelheim International GmbH $19.67 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631421
Principal investigator 1 Boehringer Ingelheim International GmbH $8.33 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631423
Principal investigator 1 Boehringer Ingelheim International GmbH $19.67 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631425
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 07/16/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631427
Principal investigator 1 Ocular Therapeutix, Inc. $142.99 07/16/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240275
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 07/16/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240277
Principal investigator 1 Ocular Therapeutix, Inc. $59.34 07/11/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240273
Principal investigator 1 Ocular Therapeutix, Inc. $581.44 07/09/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240271
Principal investigator 1 Ocular Therapeutix, Inc. $2,331.90 07/02/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240269
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631429
Recipient Ocular Therapeutix, Inc. $11,185.41 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229263
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 06/23/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240259
Principal investigator 1 Ocular Therapeutix, Inc. $8,645.41 06/13/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240255
Principal investigator 1 Ocular Therapeutix, Inc. $5,558.15 06/13/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240257
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631431
Principal investigator 1 KYOWA KIRIN, INC. $4,210.44 05/29/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806348
Principal investigator 1 KYOWA KIRIN, INC. $6,377.85 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.20 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/28/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184199701
Principal investigator 1 Ocular Therapeutix, Inc. $1,461.68 05/23/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240251
Principal investigator 1 Ocular Therapeutix, Inc. $3,171.60 05/23/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240253
Principal investigator 1 Ocular Therapeutix, Inc. $4,128.30 05/21/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240249
Principal investigator 1 KYOWA KIRIN, INC. $4,210.44 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $835.90 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $754.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $357.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $754.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.20 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.70 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $188.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $357.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $188.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.70 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 05/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184196667
Principal investigator 1 KYOWA KIRIN, INC. $3,006.86 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805660
Principal investigator 1 KYOWA KIRIN, INC. $6,000.62 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805667
Principal investigator 1 KYOWA KIRIN, INC. $6,000.62 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805679
Principal investigator 1 KYOWA KIRIN, INC. $3,006.86 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.20 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,612.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.20 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.20 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,612.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.50 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.20 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.80 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184195841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,572.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184195843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184195845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 05/15/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184195847
Principal investigator 1 Ocular Therapeutix, Inc. $9,368.10 05/14/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 05/12/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 05/12/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/12/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/12/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 05/12/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194445
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 05/09/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.70 05/08/2025 Non-covered Recipient Entity
CHARLESTON NEUROSCIENCE INSTITUTE LLC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.70 05/08/2025 Non-covered Recipient Entity
CHARLESTON NEUROSCIENCE INSTITUTE LLC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 05/08/2025 Non-covered Recipient Entity
CHARLESTON NEUROSCIENCE INSTITUTE LLC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 05/08/2025 Non-covered Recipient Entity
CHARLESTON NEUROSCIENCE INSTITUTE LLC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 05/08/2025 Non-covered Recipient Entity
CHARLESTON NEUROSCIENCE INSTITUTE LLC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 05/08/2025 Non-covered Recipient Entity
CHARLESTON NEUROSCIENCE INSTITUTE LLC
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184194103
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/06/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631443
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/06/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631445
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631387
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 05/01/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631389
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 05/01/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631391
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 05/01/2025 Non-covered Recipient Entity
The Retina Partners-Encino
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220631393
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 04/30/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240243
Principal investigator 1 Ocular Therapeutix, Inc. $15,932.91 04/16/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240241
Principal investigator 1 KYOWA KIRIN, INC. $6,221.76 04/14/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803305
Principal investigator 1 KYOWA KIRIN, INC. $2,985.90 04/14/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803313
Principal investigator 1 KYOWA KIRIN, INC. $875.00 04/14/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803322
Principal investigator 1 KYOWA KIRIN, INC. $3,010.00 04/14/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803334
Principal investigator 1 KYOWA KIRIN, INC. $5,895.18 04/10/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803195
Principal investigator 1 KYOWA KIRIN, INC. $6,099.57 04/10/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803209
Principal investigator 1 KYOWA KIRIN, INC. $5,895.17 04/10/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803218
Recipient Regeneron Pharmaceuticals, Inc. $244.98 04/04/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116725
Recipient Regeneron Pharmaceuticals, Inc. $65.00 04/04/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116727
Principal investigator 1 Ocular Therapeutix, Inc. $3,171.60 03/21/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240265
Principal investigator 1 Ocular Therapeutix, Inc. $7,800.00 03/21/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240267
Principal investigator 1 Ocular Therapeutix, Inc. $4,014.00 03/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240263
Principal investigator 1 Ocular Therapeutix, Inc. $3,387.04 03/12/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.98 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.96 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.08 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $463.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.53 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.72 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $238.42 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $320.32 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $266.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.08 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $463.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $327.15 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.09 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.09 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.46 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.46 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.53 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.62 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.96 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.44 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.72 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.72 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.44 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.62 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.66 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.09 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.66 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.98 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $327.15 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.09 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.06 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $407.10 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.66 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.46 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.44 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.72 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.62 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.44 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.62 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184164997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.98 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.96 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.08 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $463.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.62 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $266.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.66 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.98 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.08 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $463.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.44 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.72 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.53 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.46 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.96 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $407.10 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $238.42 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $320.32 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.53 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.46 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $327.15 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.09 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.06 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.44 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $407.10 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $238.42 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $320.32 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $266.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $463.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $463.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184165861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.09 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.66 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.98 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.62 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.70 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.96 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.08 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.53 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.66 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.82 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.72 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.53 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.46 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.96 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.08 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.80 03/07/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166411
Recipient Regeneron Pharmaceuticals, Inc. $408.07 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116713
Recipient Regeneron Pharmaceuticals, Inc. $150.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116715
Recipient Regeneron Pharmaceuticals, Inc. $81.75 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116717
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116719
Recipient Regeneron Pharmaceuticals, Inc. $79.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116721
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116723
Recipient Regeneron Pharmaceuticals, Inc. $612.00 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116709
Recipient Regeneron Pharmaceuticals, Inc. $184.25 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184116711
Principal investigator 1 Ocular Therapeutix, Inc. $3,690.90 02/19/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240239
Principal investigator 1 Ocular Therapeutix, Inc. $3,171.60 02/05/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240237
Principal investigator 1 Ocular Therapeutix, Inc. $12,800.00 01/13/2025 Non-covered Recipient Entity
THE RETINA PARTNERS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250240235